Two breaking studies published in a recent Neurology supplement issue demonstrated the long-term, real-world efficacy and safety of erenumab for prevention of chronic and episodic migraine.

Erenumab is a anti-CGRP agonist administered once-monthly via a single-dose autoinjector in either 70mg/mL or 140 mg/mL doses.

The study abstracts were to be presented as part of the cancelled AAN 2020 Annual Meeting. 

Researchers presented the 4+ year results of a 5-year open-label trial of erenumab in 250 patients who switched from 70mg dose to 140mg dose after approximately 2 years of monthly treatment.

Change from baseline 8.7 monthly migraine days was -5.8 days overall. Additionally, among patients taking acute migraine-specific medication change from baseline was -4.6 monthly migraine days.

“In this interim analysis, long-term erenumab treatment (4+ years) demonstrated sustained reductions in migraine frequency and was well-tolerated and safe,” Messoud Ashina , MD, PhD, director of the Human Migraine Research Unit at the Danish Headache Centre and Department of Neurology, Glostrup Hospital, and colleagues wrote.

The researcher found that there were no new safety profiles or increases in adverse events over the 4+ year study compared to clinical trials.

Another abstract in the supplement reported on real-world, 1 year data of erenumab use from 70 headache centers in Germany.

This study showed that 80% of 109 patients taking erenumab reported reduced migraine intensity and 92% of patients reported a reduction in migraine frequency.

“These newly shared data reinforce Novartis commitment to reimagine migraine care and add to the growing body of real world and long-term evidence demonstrating the efficacy of [erenumab] for migraine prevention across the migraine spectrum,” Estelle Vester-Blokland, MD, Global Head Neuroscience Medical Affairs, Novartis Pharmaceuticals, said in a press release.